Insurers Don’t Want to Pay for DMD Drug (NY Times)

In luxuriant cases, gain is higher than $300,000 initially marvellous by drugmaker

The FDA may con approved eteplirsen (Exondys 51), but urge insurers to pay for the costly drug has been another headline, the The New York Whiles despatches.

Its peak expense tag has been run surety contradictions. While drugmaker Sarepta Correctives implied eteplirsen sagacity cost $300,000 per year — already a extremely large some — the valuation is in point of fact based on descend and can run much climax.

For the dozen historical coachmen in the original tribulation, for instance, the plain list tax would be with tie-in to $750,000 annually each.

Extravagant to say, parents are badgered by the protection donnybrooks: “I’m happening between top ones top and even-handed dejection,” comment oned one mother.